| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 44 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 44 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 44 |
| 3 | DEXAMETHASONE | 36 |
| 4 | DEXAMETHASONE 1.5 MG | 36 |
| 5 | LENALIDOMIDE | 33 |
| 6 | MELPHALAN HYDROCHLORIDE | 27 |
| 7 | MELPHALAN | 21 |
| 8 | FLUDARABINE PHOSPHATE | 20 |
| 9 | RITUXIMAB | 16 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CARMUSTINE | 8 | 0.0017 |
| 1 | IBRITUMOMAB TIUXETAN | 2 | 0.0013 |
| 2 | MITOXANTRONE HYDROCHLORIDE | 7 | 0.0011 |
| 3 | MELPHALAN HYDROCHLORIDE | 27 | 0.0011 |
| 4 | SODIUM IODIDE I 123 | 1 | 0.0011 |
| 5 | SODIUM IODIDE I 131 | 1 | 0.0010 |
| 6 | VINBLASTINE SULFATE | 2 | 0.0010 |
| 7 | CLADRIBINE | 6 | 0.0006 |
| 8 | ROMIDEPSIN | 1 | 0.0006 |
| 9 | SARGRAMOSTIM | 1 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 48 |
| 1 | Corticosteroid [EPC] | 43 |
| 2 | Thalidomide Analog [EPC] | 33 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 17 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 15 |
| 5 | Proteasome Inhibitor [EPC] | 15 |
| 6 | Topoisomerase Inhibitor [EPC] | 15 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 8 |
| 8 | Platinum-based Drug [EPC] | 8 |
| 9 | Purine Antimetabolite [EPC] | 7 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 2 | 0.0004 |
| 1 | Histone Deacetylase Inhibitor [EPC] | 1 | 0.0003 |
| 2 | Alkylating Drug [EPC] | 48 | 0.0002 |
| 3 | Topoisomerase Inhibitor [EPC] | 15 | 0.0002 |
| 4 | Proteasome Inhibitor [EPC] | 15 | 0.0001 |
| 5 | Purine Antimetabolite [EPC] | 7 | 0.0001 |
| 6 | Thrombopoietin Receptor Agonist [EPC] | 1 | 0.0001 |
| 7 | Thalidomide Analog [EPC] | 33 | 0.0001 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 15 | 0.0001 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 17 | 0.0001 |